Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Conference News TCT 2024

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

Michael O'Riordan

October 28, 2024

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

L.A. McKeown

October 28, 2024

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

L.A. McKeown

September 23, 2022

News Conference News TCT 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Yael L. Maxwell

November 05, 2021

News Conference News TCT 2020

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

Caitlin E. Cox

October 14, 2020

News Conference News TCT 2018

Prosthetic Valve Endocarditis Rate Similarly Low for TAVR vs SAVR

TCT Daily Staff

September 28, 2018

News Conference News TCT 2017

TAVR Beats Out SAVR, at Least In-Hospital, for Patients With Prior CABG

Ashley Lyles

November 08, 2017

News Conference News TCT 2016

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Todd Neale

November 02, 2016

News Conference News TCT 2015

Initial Surgical AVR Improves Long-term Outcomes in Asymptomatic Patients With Severe AS

October 15, 2015

News Conference News TCT 2015

Current State of Percutaneous Valve Therapies for Use in Congestive HF Explored

October 13, 2015

Presentation TCT 2014

Position Statement: TAVR Will Replace Surgical AVR in Low- and Intermediate-Risk Patients: Cath Labs Get Ready!

Presenter: Kishore J. Harjai, Susheel Kodali

September 14, 2014

News Conference News TCT 2013

TAVR, Surgical AVR Patients Show Similar Rates of Neurological Damage

November 03, 2013

Presentation TCT 2013

Motion: The Envelope for TAVR Should be Expanded to All Candidates for Conventional AVR - For: The Data are Clear (And Common Sense Rules): TAVR is a Lower Risk Option than...

Presenter: Daniel Blackman

October 30, 2013

Presentation TCT 2013

Motion: The Envelope for TAVR Should be Expanded to All Candidates for Conventional AVR - Against: The TAVR Data are Only on High-Risk Patients with Limited Follow-Up

Presenter: Charles Davidson

October 30, 2013

Presentation TCT 2013

Predicting the Future in Five Years: How Much AS Will Be Treated with TAVR vs AVR?

Presenter: Larry Wood

October 29, 2013

Presentation TCT 2013

The High Frequency and Insidious Consequences of Bleeding Events After TAVR (and Surgical AVR)

Presenter: Philippe Généreux

October 28, 2013

Presentation TCT 2013

Incidence, Predictors, and Outcomes of Strokes After Surgical AVR and TAVR

Presenter: D. Craig Miller

October 28, 2013

Presentation TCT 2013

Which High-Risk AS Patients Should be Treated with TAVR and Which are Better Suited for Surgical AVR

Presenter: Neil Moat

October 27, 2013

Presentation TCT 2013

My Crystal Ball: The Future of Surgical AVR in the Era of TAVR

Presenter: Craig Smith

October 27, 2013

Advertisement

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

Prosthetic Valve Endocarditis Rate Similarly Low for TAVR vs SAVR

TAVR Beats Out SAVR, at Least In-Hospital, for Patients With Prior CABG

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Initial Surgical AVR Improves Long-term Outcomes in Asymptomatic Patients With Severe AS

Current State of Percutaneous Valve Therapies for Use in Congestive HF Explored

Position Statement: TAVR Will Replace Surgical AVR in Low- and Intermediate-Risk Patients: Cath Labs Get Ready!

TAVR, Surgical AVR Patients Show Similar Rates of Neurological Damage

Motion: The Envelope for TAVR Should be Expanded to All Candidates for Conventional AVR - For: The Data are Clear (And Common Sense Rules): TAVR is a Lower Risk Option than...

Motion: The Envelope for TAVR Should be Expanded to All Candidates for Conventional AVR - Against: The TAVR Data are Only on High-Risk Patients with Limited Follow-Up

Predicting the Future in Five Years: How Much AS Will Be Treated with TAVR vs AVR?

The High Frequency and Insidious Consequences of Bleeding Events After TAVR (and Surgical AVR)

Incidence, Predictors, and Outcomes of Strokes After Surgical AVR and TAVR

Which High-Risk AS Patients Should be Treated with TAVR and Which are Better Suited for Surgical AVR

My Crystal Ball: The Future of Surgical AVR in the Era of TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content